Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 16/20 | 0.78 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.78 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.78 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.78 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547144 | 1.00 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15753075 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL19253209 | 0.88 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15921393 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15753296 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL14880426 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL17164619 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL17164640 | 0.88 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL19733234 | 0.88 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL19253156 | 0.86 | GRIN1 (1.00) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379542-A2 | TREATMENT OF TUMOURS | Hagström, Tomas (SE) | 2004-01-14 | — | — | EP | claimed |
| WO-2002072003-A2 | USE OF STEROID DERIVATIVES FOR THE TREATMENT OF A BENIGHN AND/OR MALIGNANT TUMOUR | HAGSTROEM TOMAS (SE) | 2002-09-19 | — | — | WO | claimed |
| US-20070111973-A1 | TREATMENT OF TUMOURS | HAGSTROM TOMAS | 2007-05-17 | — | — | US | disclosed |
| US-20050192262-A1 | Treatment of tumours | HAGSTROM, TOMAS (SE) | 2005-09-01 | — | — | US | disclosed |
| EP-1379542-A2 | TREATMENT OF TUMOURS | Hagström, Tomas (SE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002072003-A2 | USE OF STEROID DERIVATIVES FOR THE TREATMENT OF A BENIGHN AND/OR MALIGNANT TUMOUR | HAGSTROEM TOMAS (SE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192262-A1 | Treatment of tumours | SULT2A1, SULT1A1, HSD17B11 | GRIN1 3758/4885GRIN2B 3712/4885GRIN2D 3945/4885 |
| US-20070111973-A1 | TREATMENT OF TUMOURS | SULT2A1, SULT1A1, SULT1E1 | GRIN1 3279/4885GRIN2B 3364/4885GRIN2D 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.